drugset / Trial / NCT02174510
A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
Phase 1
Completed
37 enrolled
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Xuhui Central Hospital, Shanghai · collab
RandomizedParallel-groupTriple-blindBasic science
Summary
To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects. To evaluate the safety and tolerability of lurasidone after single oral administration of different doses in healthy Chinese subjects.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 20 mg | Oral |
| Subject | Lurasidone | Small molecule | 40 mg | Oral |
| Subject | Lurasidone | Small molecule | 80 mg | Oral |